Medical World News

[Preciouslife1]

$HGEN Unlike Edgewise Therapeutics, Humanigen (NASDAQ:HGEN) is a more mature company, boasting a handful of late-stage clinical trials in its field of immuno-oncology. But aside from one program, it doesn't focus on making drugs that target cancers directly. Instead, the company's headliner pipeline projects are intended to stop a sometimes-deadly immunotherapy side effect called cytokine storm. In a nutshell, that means its drugs could become must-buy emergency tools for oncology clinics that want to use cutting-edge therapies with as little risk to patients as possible.

Given that immunotherapies have become more and more common over the last decade, there will likely be an increasing demand for therapies like Humanigen's. But there's another major catalyst for growth in the anti-cytokine storm therapy market: COVID-19. Severe coronavirus infections are associated with cytokine storms, and the company is moving fast to provide a solution. So far, there's no other approved products in the space, which makes its project all the more compelling.

Its antibody therapy lenzilumab was shown in a phase 3 clinical trial to reduce the risk of hospitalized coronavirus patients needing ventilators or dying by 54%. That's great news, and it also means that the drug could be given emergency use authorization in a few months. So, investors could start to see new revenue from sales of lenzilumab before the end of 2021, which is a strong argument for purchasing the stock now.

https://www.fool.com/investing/2021/04/20/2-juicy-biotech-stocks-to-consider-buying-right-no/